Close
4

Quotient Sciences Quotient Sciences

X

Company profile for Autifony Therapeutics

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
Autifony Therapeutics Limited is a UK-based company formed in 2011 as a spin-out from GlaxoSmithKline by Charles Large and Giuseppe Alvaro, previously Directors in GSK’s Neuroscience Centre of Excellence for Drug Discovery. Autifony is using its pioneering approach to develop novel treatments for serious disorders of the central nervous system, such as Schizophrenia, Fragile X, Alzheimer’s Disease and potentially other di...
Autifony Therapeutics Limited is a UK-based company formed in 2011 as a spin-out from GlaxoSmithKline by Charles Large and Giuseppe Alvaro, previously Directors in GSK’s Neuroscience Centre of Excellence for Drug Discovery. Autifony is using its pioneering approach to develop novel treatments for serious disorders of the central nervous system, such as Schizophrenia, Fragile X, Alzheimer’s Disease and potentially other diseases which represent major unmet medical needs. The company is also one of the leaders in pharmaceutical approaches to the treatment of hearing disorders.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
Autifony Therapeutics
unitedkingdom_new Flag
Country
Country
United Kingdom
Address
Address
Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2FX,
Telephone
Telephone
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY